Fundraising Fox
/Companies
Sign in

OncoMyx Therapeutics

Phoenix, US · Founded 2018 · Delaware corporation · 9 known investors

Find your way into OncoMyx Therapeutics

Sign up to find every way you can get introduced to OncoMyx Therapeutics

  • Your email: who you already know at OncoMyx Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the OncoMyx Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in
Biotech

Founders & leadership

OncoMyx Therapeutics was founded in 2018 by Douglas Grant McFadden, Ph.D. and Steven J. Potts, Ph.D..

DG
Douglas Grant McFadden, Ph.D.Co-founder
SJ
Steven J. Potts, Ph.D.President and Chief Executive Officer
TX
Ting XiaoNamed on SEC filing
JRJason Rushton
Jason RushtonNamed on SEC filingPartner, Investments at Xeraya Capital
KD
Kanad Das, Ph.D.Named on SEC filing
MG
Michael G. WoodNamed on SEC filing

Investors · 9

B Capital GroupreportedSan Francisco · $10M – $50M

How we know: lumiraventures.com · Not right? Tell us

Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M

How we know: funding news · lumiraventures.com · Not right? Tell us

City Hill VenturesreportedSan Diego · $100K – $20M

How we know: funding news · lumiraventures.com · Not right? Tell us

Delos CapitalreportedCambridge

How we know: funding news · lumiraventures.com · Not right? Tell us

Korea Investment PartnersreportedSeoul · $973K – $50M

How we know: lumiraventures.com · Not right? Tell us

Lumira VenturesreportedToronto · $1M – $10M

How we know: funding news · lumiraventures.com · Not right? Tell us

LYZZ CapitalreportedShanghai

How we know: funding news · lumiraventures.com · Not right? Tell us

Also in the syndicate · 1

Madison Partners

Reported raises · per SEC filings

Form D private placements

$58M disclosed across 2 rounds · 2019–2021

▶$50MraisedDec 2021 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven J. Potts, Ph.D.Executive Officer, Director
  • Kanad Das, Ph.D.Director
  • Ting Xiao, C.F.A., F.R.M.Director
  • Benjamin Rovinski, Ph.D.Director
  • Widya Mulyasasmita, Ph.D.Director
  • Charles M. Baum, M.D., Ph.D.Director
  • Leslie Sharp, Ph.D.Executive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Nov 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedJun 2019 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ting XiaoDirector
  • Jason RushtonDirector
  • Douglas Grant McFadden, Ph.D.Director
  • Kanad Das, Ph.D.Director
  • Steven J. Potts, Ph.D.Director, Executive Officer
  • Michael G. WoodExecutive Officer
Offering amount
$25M
Amount sold
$8M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who founded OncoMyx Therapeutics?
OncoMyx Therapeutics was founded by Douglas Grant McFadden, Ph.D., Steven J. Potts, Ph.D. in 2018.
Who are OncoMyx Therapeutics's investors?
OncoMyx Therapeutics's investors include Xeraya Capital, B Capital Group, Boehringer Ingelheim Venture Fund, City Hill Ventures, Delos Capital, Korea Investment Partners, Lumira Ventures, LYZZ Capital.
How much funding has OncoMyx Therapeutics raised?
OncoMyx Therapeutics has disclosed $58M raised across 2 rounds.
Where is OncoMyx Therapeutics headquartered?
OncoMyx Therapeutics is headquartered in Phoenix, US.